Evidence map›Paper›PMID 29391042›Full record

SynthesisParasites & vectors2018

Economic evaluations of lymphatic filariasis interventions: a systematic review and research needs.

Lukyn M Gedge, Alison A Bettis, Mark H Bradley, T Déirdre Hollingsworth, Hugo C Turner

Abstract readSystematic Review
In one paragraph

Synthesis in Parasites & vectors, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. What Can Modeling Tell Us About Sustainable End Points for Neglected Tropical Diseases?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Article
  14. Article
  15. Article
  16. Article
  17. The Health and Economic Burdens of Lymphatic Filariasis Prior to Mass Drug Administration Programs.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
  18. The health and economic burden of podoconiosis in Ethiopia.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2020
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lukyn M GedgeSchool of Public Health, Faculty of Medicine, St Marys Campus, Imperial College London, Norfolk Place, London, W2 1PG, UK.
Alison A BettisLondon Centre for Neglected Tropical Disease Research, London, UK.
Mark H BradleyGlobal Health Programs, GlaxoSmithKline, Brentford, UK.
T Déirdre HollingsworthMathematics Institute, University of Warwick, Coventry, CV4 7AL, UK.
Hugo C TurnerOxford University Clinical Research Unit, Wellcome Trust Major Overseas Programme, Ho Chi Minh City, Vietnam. hturner@oucru.org.

Funding

Wellcome TrustWellcome Trust 089276/B/09/7
6 · The paper itself

Abstract

In 2000, the World Health Organization established the Global Programme to Eliminate Lymphatic Filariasis (GPELF), with the goal of eliminating the disease as a public health problem by 2020. Since the start of the programme, a cumulative total of 6.2 billion treatments have been delivered to affected populations - with more than 556 million people treated in 2015 alone. In this paper, we perform a rigorous systematic review of the economic evaluations of lymphatic filariasis interventions have been conducted. We demonstrate that the standard interventions to control lymphatic filariasis are consistently found to be highly cost-effective. This finding has important implications for advocacy groups and potential funders. However, there are several important inconsistencies and research gaps that need to be addressed as we move forward towards the 2020 elimination goals. One of the most important identified research gaps was a lack of evaluation of new interventions specifically targeting areas co-endemic with onchocerciasis and Loa loa - which could become a major barrier to achieving elimination.

Indexed as

Cost-Benefit AnalysisElephantiasis, FilarialFilaricidesHumansFilaricidesCost-benefitCost-effectivenessEconomic evaluationsEconomic impactGPELFLymphatic filariasisProgramme evaluation

Identifiers

PMID29391042
PMCPMC5793442

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.